Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Afib

    Current Location

    Search
    Afib
    Show Map
    Map View
    Your Location
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Clear All

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      53 Afib Trials Near You

      Power is an online platform that helps thousands of Afib patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Milvexian vs Apixaban for Atrial Fibrillation

      Rockville, Maryland
      This trial is testing a new medication called milvexian to see if it can prevent strokes and blood clots as well as an existing drug, apixaban. Apixaban (Eliquis™) was developed by Bristol-Myers Squibb and Pfizer and has been approved for the prevention of stroke in patients with certain heart conditions. The study focuses on patients who are at risk of these serious conditions. Milvexian works by helping to keep the blood flowing smoothly, reducing the chances of dangerous clots forming.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Valve Disease, Others
      Must Be Taking:Anticoagulants

      20296 Participants Needed

      Pacing Rates for Atrial Fibrillation

      Fairfax, Virginia
      This is a prospective, randomized crossover study. The objective of the study is to determine if a pacing rate of 80 beats per minute (bpm) improves exercise tolerance during the 6-minute walk test. The investigators will randomly assign half of the participants to a starting rate of 60 bpm and then switch them to a rate of 80 bpm for 3 months, and vice versa.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Severe CAD, ESRD, Pulmonary Disease, Others

      60 Participants Needed

      Abelacimab vs. Rivaroxaban for Atrial Fibrillation

      Manassas, Virginia
      This trial is testing a new blood thinner called abelacimab to see if it causes less bleeding compared to an existing drug, rivaroxaban. It focuses on patients with atrial fibrillation who are at a higher risk of stroke. Blood thinners help prevent strokes by stopping clots, but they can also cause bleeding.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:55+

      Key Eligibility Criteria

      Disqualifiers:Intracranial Bleed, Mechanical Heart Valve, Others
      Must Be Taking:Anticoagulants

      1287 Participants Needed

      Ablation for Atrial Fibrillation and Heart Failure

      Fairfax, Virginia
      This is a prospective non-blinded randomized control pilot study comparing the effect of pulmonary vein isolation against medical management of atrial fibrillation in patients with Heart Failure with preserved Ejection Fraction (HFpEF).
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      60 Participants Needed

      Abelacimab for Atrial Fibrillation

      Falls Church, Virginia
      This trial is testing abelacimab, a medication aimed at preventing strokes and blood clots in people with Atrial Fibrillation. These patients are either unsuitable for or have chosen not to use common medications for thinning blood. Abelacimab works by reducing the blood's ability to form dangerous clots.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:65+

      Key Eligibility Criteria

      Disqualifiers:Acute Reversible AF, Recent Stroke, Others
      Must Not Be Taking:Vitamin K Antagonists, DOACs

      1900 Participants Needed

      Tailored Catheter Ablation for Atrial Fibrillation

      Fairfax, Virginia
      This trial is testing a computer program combined with a medical procedure to help patients whose irregular heartbeat has returned. The program helps doctors find and fix the problem areas in the heart more effectively.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:21+

      Key Eligibility Criteria

      Disqualifiers:Obesity, Heart Failure, Pregnancy, Others
      Must Be Taking:Anticoagulants

      92 Participants Needed

      Cryoballoon Ablation for Persistent Atrial Fibrillation

      Washington, District of Columbia
      The purpose of this study it to learn whether pulmonary vein isolation (PVI) along with isolation of the posterior left atrial wall (PWI) in the region of the pulmonary venous component will reduce the likelihood of atrial fibrillation (AF) recurrence in patients with persistent atrial fibrillation at 12 months, after a single ablation procedure, in comparison to PVI alone. The investigator hypothesizes that the combination of PVI + PWI will result in a significant reduction in recurrence of atrial fibrillation at 12 months after ablation.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      153 Participants Needed

      Apixaban vs Aspirin for Stroke Prevention in Atrial Fibrillation After Brain Bleed

      Falls Church, Virginia
      Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Active Endocarditis, Hepatitis, Anemia, Others
      Must Not Be Taking:Anticoagulants, Antiplatelets

      700 Participants Needed

      Anticoagulation + Antiplatelet Therapy for Post-Operative Atrial Fibrillation

      Bethesda, Maryland
      The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Permanent AF, Cardiogenic Shock, Liver Cirrhosis, Others
      Must Not Be Taking:Dual Antiplatelets

      3200 Participants Needed

      WATCHMAN FLX Device for Atrial Fibrillation

      Falls Church, Virginia
      The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Active Bleed, Recent Stroke, Others
      Must Be Taking:Non-vitamin K Anticoagulants

      3000 Participants Needed

      EGF Mapping and Ablation Therapy for Atrial Fibrillation

      Falls Church, Virginia
      Demonstrate the safety and effectiveness of the Ablacath™ Mapping Catheter and Ablamap® System in patients with all types of atrial fibrillation (AF) including paroxysmal or persistent or long-standing persistent, undergoing and De Novo or Redo procedures. Phenotype patients and demonstrate the prognostication power of Electrographic Flow (EGF®) maps among all subjects using 12-month follow-up outcomes following EGF-guided mapping and ablation.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:De Novo Paroxysmal AF, Reversible AF, Recent Cardiac Surgery, Severe Valvular Disease, Decompensated Heart Failure, Others

      400 Participants Needed

      Smartwatch-Guided DOAC Therapy for Atrial Fibrillation

      Washington, District of Columbia
      This trial tests whether taking blood-thinning medication continuously or only when a smart watch detects an irregular heartbeat is better for adults with a history of irregular heartbeats and moderate stroke risk.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:22 - 85

      Key Eligibility Criteria

      Disqualifiers:Valvular AF, Pregnancy, Hypertrophic Cardiomyopathy, Others
      Must Be Taking:DOACs

      5350 Participants Needed

      Cryoablation + LAA Closure for Atrial Fibrillation

      Washington, District of Columbia
      The primary objective of this study is to evaluate the safety and effectiveness of the AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with Left Atrial Appendage (LAA) exclusion using the AtriClip device.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Heart Failure, Stroke, Infection, Others
      Must Not Be Taking:Anti-arrhythmics, Chemotherapy, Steroids, Others

      150 Participants Needed

      CLAAS Device for Atrial Fibrillation

      Washington, District of Columbia
      This trial is testing a new heart device called the CLAAS® to see if it works as well as other similar devices. It is aimed at patients with a specific type of irregular heartbeat that can lead to strokes. The device helps by blocking off a small part of the heart to stop blood clots from forming.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Infection, Stroke, Heart Failure, Others
      Must Not Be Taking:Antiplatelets, Anticoagulants

      1600 Participants Needed

      WATCHMAN FLX Pro Device for Atrial Fibrillation

      Washington, District of Columbia
      The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Severe Liver Disease, Hypercoagulability, Stroke, Others
      Must Not Be Taking:Anticoagulants, P2Y12 Inhibitors

      1857 Participants Needed

      Left Atrial Appendage Occlusion vs. NOAC for Atrial Fibrillation

      Washington, District of Columbia
      The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Mechanical Valve, Severe Renal Failure, Others
      Must Be Taking:NOACs

      2650 Participants Needed

      Wearable Cardiac Monitor for Atrial Fibrillation

      Baltimore, Maryland
      Screening for Atrial Fibrillation in Elderly Women (SAFE-W) is a pilot study evaluating the prevalence of atrial fibrillation (Afib) in a rapidly aging segment of the population. Studies have shown that women with Afib are more likely to be symptomatic, have increased mortality from stroke resulting from Afib, and are less likely to receive treatment for Afib. University of Maryland Department of Neurology and Vascular Neurology are recruiting women older than 70 years of age to participate in the study.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:70 - 100
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Life Expectancy < 2 Years, Dementia, Others

      120 Participants Needed

      RF Ablation for Atrial Fibrillation

      Baltimore, Maryland
      The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Previous Cardiac Surgery, Renal Dysfunction, Others
      Must Be Taking:Class I/III AAD

      325 Participants Needed

      PVI vs PVI + OPTIMA Ablation for Atrial Fibrillation

      Baltimore, Maryland
      This trial tests a new method called OPTIMA for treating persistent atrial fibrillation (AF). It aims to better target problem areas in the heart to improve treatment success for patients who haven't responded well to other treatments.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Obesity, Low GFR, Others
      Must Be Taking:Anticoagulants

      200 Participants Needed

      CT for Atrial Fibrillation

      Baltimore, Maryland
      This study explores the relationship between myocardial fibrosis and patient outcomes in Atrial Fibrillation (AF), specifically after catheter ablation. It aims to use Cardiac CT, an accessible tool, to measure left ventricular extracellular volume (ECV) as an indicator of fibrosis. The study will assess if higher ECV levels correlate with increased risks of AF recurrence, hospitalization, and poor cardiac function recovery. Positive findings could make ECV a key factor in deciding AF treatment strategies.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:21+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Heart Transplant, Severe Claustrophobia, Others

      100 Participants Needed

      Why Other Patients Applied

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78
      Match to a Afib Trial

      Globe Pulsed Field Ablation for Atrial Fibrillation

      Baltimore, Maryland
      This trial is testing a new device that uses electrical pulses to treat people with irregular heartbeats. It focuses on patients who have noticeable symptoms of occasional or ongoing atrial fibrillation. The goal is to see if the device is safe and effective.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Long-standing AF, Thromboembolic Events, MI, Others

      549 Participants Needed

      FARAPULSE Ablation for Atrial Fibrillation

      Baltimore, Maryland
      This trial is testing a device that uses electrical pulses to treat patients with persistent atrial fibrillation who do not respond to drugs. The device works by creating small scars in the heart to block abnormal electrical signals and restore normal rhythm.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      669 Participants Needed

      Mobile Health Technology for Atrial Fibrillation

      Baltimore, Maryland
      The overall objective of this proposal is to evaluate the effect on quality of life of a comprehensive digital atrial fibrillation (AFib) management tool that will empower patients to a) take an active role in learning about AFib management options, starting and adhering to evidence-based therapies and lifestyle changes and b) to guide the patients during AFib episodes which are associated with anxiety and impairment in quality of life. Researchers plan to evaluate the effectiveness of this novel digital toolkit in improving quality of life and decreasing AFib burden in a randomized clinical trial (RCT). A pilot study assessing feasibility and retention of the intervention was previously conducted (NCT05400837)
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Permanent Afib, Severe Valvular Disease, Others

      248 Participants Needed

      HeartLight Ablation for Atrial Fibrillation

      Charlottesville, Virginia
      This is a post-approval study to evaluate the clinical outcomes in a cohort of participants treated during commercial use of the HeartLight System to confirm results of the previously conducted pivotal clinical study.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Good Health, Others
      Must Be Taking:Anti-arrhythmics

      250 Participants Needed

      WATCHMAN Device for Atrial Fibrillation

      Charlottesville, Virginia
      LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Age < 18, Thrombus, Prior Occlusion, Others
      Must Be Taking:Oral Anticoagulants

      4000 Participants Needed

      Renal Denervation for Atrial Fibrillation

      Richmond, Virginia
      This is a Prospective, controlled, single-blind, randomized (2:1, Intervention:Control) clinical trial. The purpose of the study is to determine the role of adjunctive renal sympathetic denervation in the prevention of Atrial Fibrillation (AF) recurrence in patients with hypertension scheduled for a redo AF ablation procedure for paroxysmal or persistent AF. Patients will be randomized to either i) AF ablation (Control) or ii) AF ablation + renal sympathetic denervation (Intervention).
      Stay on current meds
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Long-standing AF, NYHA Class IV, Others
      Must Be Taking:Antihypertensives

      250 Participants Needed

      Esophageal Cooling During Ablation for Atrial Fibrillation

      Richmond, Virginia
      Atrial fibrillation (AF) is a common debilitating heart rhythm condition that can cause heart failure and negatively impact a patient's outlook in terms of symptoms and disability. It is an irregular fast heart rhythm disorder coming from the top chamber of the heart (left atrium). Catheter ablation treatment has been shown to be effective in controlling or eliminating AF and its associated symptoms. This is now a common and effective treatment option for patients suffering with AF. During ablation, thermal energy is applied in the top chamber of the heart (the left atrium) to abolish abnormal electrical signals that cause AF. It is generally a safe procedure, but one potential risk associated with this procedure is damage to the esophagus caused by thermal energy being transmitted to the esophagus from the heart. The esophagus sits just behind the heart chamber where ablation work is performed, about 5mm away, so it is vulnerable to damage. Although the risk of severe esophageal damage is low, if it occurs it can be serious as the patient may become very ill as a result. In recent studies, it was shown that a more advanced type of esophageal probe (ensoETM) that cools the esophagus during ablation is better at protecting the esophagus from ablation-related injury compared to the standard care temperature monitoring probe currently used. The ensoETM is a CE marked and FDA-cleared device, with an intended purpose of controlling patient temperature and has received marketing authorization from FDA to reduce the likelihood of ablation-related esophageal injury resulting from radiofrequency cardiac ablation procedures. The purpose of this study is to determine if the long-term efficacy outcome results obtained in single pilot studies can be replicated in a prospective, multi-center randomized controlled trail comparing the the esophageal cooling probe versus a standard of care esophageal temperature monitoring probe. There is a 50:50 chance of the esophageal cooling probe being used during AF ablation for participants.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Inability To Consent, Age <18 Or >85, Recent Ablation, Others

      152 Participants Needed

      Left Atrial Appendage Closure Device for Atrial Fibrillation

      Bryn Mawr, Pennsylvania
      An evaluation of the safety and performance of the Conformal Left Atrial Appendage Seal for Left Atrial Appendage Occlusion
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Severe Heart Failure, Stroke, Others
      Must Be Taking:Oral Anticoagulants

      64 Participants Needed

      Surgical Ablation for Atrial Fibrillation

      Wynnewood, Pennsylvania
      The purpose of this study is to demonstrate the safety and effectiveness of the Cardioblate iRF and CryoFlex hand held devices for the treatment of non-paroxysmal AF.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Wolff-Parkinson-White, NYHA Class IV, Others
      Must Be Taking:Anticoagulants

      160 Participants Needed

      AI Mapping and Ablation for Atrial Fibrillation

      Philadelphia, Pennsylvania
      The goal of this clinical trial is to compare the use of the Vektor Computational ECG Mapping System (vMap®) with pulmonary vein isolation (PVI), to using PVI alone, to treat Atrial Fibrillation (AF) in adults. Participants will have a 50/50 or 1 out of 2 chance of being placed in the treatment or control arm. The control arm of the study involves PVI alone for ablation procedure(s). The treatment arm involves the use of vMap mapping in addition to PVI to plan ablation procedure(s).
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:22+

      Key Eligibility Criteria

      Disqualifiers:Long-standing AF, Poor ECG Quality, Pregnancy, Others

      384 Participants Needed

      12

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      Top Asthma Clinical Trials

      Top Social Anxiety Clinical Trials

      Top Hearing Loss Clinical Trials

      Top Testicular Cancer Clinical Trials

      Top Pancreas Cancer Clinical Trials

      Top Gastroenterology Clinical Trials

      Top Appendicitis Clinical Trials

      Top Glioma Clinical Trials

      Top Experimental Clinical Trials

      Top Perimenopause Clinical Trials

      Top Ebv Clinical Trials

      Top Acne Clinical Trials

      By Trial

      Pregnenolone for Chronic Traumatic Brain Injury

      Fixed Dose Triple vs Dual Combination for COPD

      Cancer Screening Methods for Prostate Cancer

      Enlicitide Decanoate for High Cholesterol

      Hyperpolarized 13C Pyruvate MRI for Kidney Cancer

      Frequency Specific Microcurrent for Osteoarthritis

      Educational Videos and Questionnaires for Bladder Cancer

      Chemotherapy for Acute Myeloid Leukemia

      Parental Feeding Practices for Childhood Obesity

      MRI + Mammography for Breast Cancer Screening

      Blood Flow Restriction Training for Muscle Weakness

      MLN0128 for Cancer

      Related Searches

      Top Thrombocytopenia Clinical Trials

      Top Mycosis-fungoides Clinical Trials

      Fisetin for Immune Deficiency-Related Lung Disease

      Mental Health App + Remote Therapy for Depression

      PD1-LAG3 Bispecific Antibody for Solid Tumors

      Symphony Thrombectomy for Pulmonary Embolism

      Semaglutide for Obesity

      Belvarafenib + Cobimetinib/Nivolumab for Melanoma

      SVV-001 + Nivolumab + Ipilimumab for Neuroendocrine Cancer

      Forimtamig-Based Combinations for Multiple Myeloma

      Androgen Deprivation Therapy for High Blood Pressure in Prostate Cancer Patients

      Abiraterone + Prednisone for Prostate Cancer

      Frequently Asked Questions

      How much do Afib clinical trials pay?
      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
      How do Afib clinical trials work?
      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Afib trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Afib is 12 months.
      How do I participate in a study as a "healthy volunteer"?
      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
      What does the "phase" of a clinical trial mean?
      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
      Do I need to be insured to participate in a Afib medical study ?
      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
      What are the newest Afib clinical trials ?
      Most recently, we added Decision Support Tool for Atrial Fibrillation, Mobile Health Technology for Atrial Fibrillation and Farapulse Catheter System for Atrial Fibrillation to the Power online platform.